Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (21-30 of 212) with videos related to

Pageof 22
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2022
Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measuresAngelique Bobrie, Marta Jarlier, Aurore Moussion, et al.
Journal of Medical Economics|August 11, 2017
Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance databasePatrick Tilleul, William Jacot, Corinne Emery, et al.
Cancer Treatment Reviews|May 10, 2011
HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancerChantal Tsé, Anne-Sophie Gauchez, William Jacot, et al.
Journal of the National Cancer Institute|December 18, 2012
Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic reviewPierre-Jean Lamy, Pierre-Marie Martin, Gilles Romieu, et al.
Frontiers in Oncology|November 19, 2019
High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic MarkerKonstantinos S Papadakos, Amélie Darlix, William Jacot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndromeJean-Louis Pujol, Anne-Laure Godard, William Jacot, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancerJean-Louis Pujol, Xavier Quantin, Didier Choma, et al.
International Journal of Molecular Medicine|April 27, 2022
<i>In situ</i> hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type‑1 in formalin‑fixed paraffin‑embedded breast cancer specimensFlorence Boissière-Michot, Caroline Mollevi, Volker Baecker, et al.
American Journal of Clinical Oncology|February 3, 2005
Multimodality treatment program in invasive thymic epithelial tumorWilliam Jacot, Xavier Quantin, Sarah Valette, et al.
Biochimica Et Biophysica Acta|May 1, 2013
The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondWilliam Jacot, Maryse Fiche, Khalil Zaman, et al.
Pageof 22

Showing results (21-30 of 212) with videos related to

Sort By:
Pageof 22
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2022
Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measuresAngelique Bobrie, Marta Jarlier, Aurore Moussion, et al.
Journal of Medical Economics|August 11, 2017
Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance databasePatrick Tilleul, William Jacot, Corinne Emery, et al.
Cancer Treatment Reviews|May 10, 2011
HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancerChantal Tsé, Anne-Sophie Gauchez, William Jacot, et al.
Journal of the National Cancer Institute|December 18, 2012
Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic reviewPierre-Jean Lamy, Pierre-Marie Martin, Gilles Romieu, et al.
Frontiers in Oncology|November 19, 2019
High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic MarkerKonstantinos S Papadakos, Amélie Darlix, William Jacot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndromeJean-Louis Pujol, Anne-Laure Godard, William Jacot, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancerJean-Louis Pujol, Xavier Quantin, Didier Choma, et al.
International Journal of Molecular Medicine|April 27, 2022
<i>In situ</i> hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type‑1 in formalin‑fixed paraffin‑embedded breast cancer specimensFlorence Boissière-Michot, Caroline Mollevi, Volker Baecker, et al.
American Journal of Clinical Oncology|February 3, 2005
Multimodality treatment program in invasive thymic epithelial tumorWilliam Jacot, Xavier Quantin, Sarah Valette, et al.
Biochimica Et Biophysica Acta|May 1, 2013
The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondWilliam Jacot, Maryse Fiche, Khalil Zaman, et al.
Pageof 22